Swedbank AB, along with other firms such as
James Hambro & Partners LLP, CHICAGO TRUST Co NA, Bath Savings Trust Co, Advisory Services Network LLC, and
Fiduciary Alliance LLC decreased their stock positions in
Danaher Corporation. Conversely,
Goldman Sachs, KeyBanc, DAVENPORT & Co LLC, Douglas Lane & Associates LLC, Phraction Management LLC, Caldwell Trust Co, and several others displayed bullish sentiment, increasing their stakes.
P/E ratio insights and the upcoming release of FQ3 results on October 21 are anticipated.
Foster Victor Wealth Advisors LLC, Voya Investment Management LLC, Fragasso Financial Advisors Inc, and others have significant positions in the company. Despite mixed fundamentals, analysts remain optimistic about Danaher's bioprocessing business and predict strong growth, substantiated by healthy Q3 earnings. Nevertheless,
Wells Fargo lowered its price target on Danaher, reflecting potential risks. Other notable relationships include
Osterweis Capital Management Inc. and
Vega Investment Solutions with positions in the company.
Rosen Law Firm initiated an investigation into potential breaches of fiduciary duty by Danaher.
Investment outlooks are mixed, with both
Jim Cramer and
Goldman Sachs showing support for Danaher. While Cramer recognized strong quarterly performance, he expressed reservations, referencing previous disappointments. A possibly shrinking Life Sciences segment sparked concern too. However, positive financial indicators and steady dividends have solidified the bull case for some. Danaher is seen as a strong player in the biotech sector – a factor instrumental in its present and future trajectory.
Danaher Corporation DHR News Analytics from Sun, 13 Apr 2025 07:00:00 GMT to Sat, 27 Dec 2025 17:11:51 GMT -
Rating 5
- Innovation 7
- Information 8
- Rumor -3
